UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K		
Pursuant to Section 13 or 15(d) of the		
Securities Exch	ange Act of 1934	

Date of Report (Date of earliest event reported): June 1, 2023 (June 1, 2023)

Humana Inc.

	Humana Inc.	
(Exact na	me of registrant as specified in it	s charter)
Delaware	1-5975	61-0647538
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
	Vest Main Street Louisville, KY 4 of principal executive offices, including 2	
(Regis	502-580-1000 trant's telephone number, including area	code)
(Former na	ame or former address, if changed since l	ast report)
Check the appropriate box below if the Form 8-K under any of the following provisions (<i>see</i> Genera		satisfy the filing obligation of the registrant
□ Written communications pursuant to Rule 42	25 under the Securities Act (17 CFI	R 230.425)
☐ Soliciting material pursuant to Rule 14a-12 u	under the Exchange Act (17 CFR 2	40.14a-12)
□ Pre-commencement communications pursua	nt to Rule 14d-2(b) under the Exch	ange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursua	nt to Rule 13e-4(c) under the Exch	ange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of t	he Act:	
<u>Title of each class</u>	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	HUM	New York Stock Exchange
Indicate by check mark whether the registrant is at Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the second seco		
Emerging growth company □		
If an emerging growth company, indicate by check complying with any new or revised financial according	•	

Item 7.01 Regulation FD Disclosure.

Members of Humana Inc.'s (the "Company") senior management team are scheduled to meet with investors and analysts at industry conferences and various other meetings between June 1, 2023 and June 30, 2023. During these conferences and meetings, the Company intends to reaffirm its guidance of at least \$27.88 in diluted earnings per common share ("EPS") or at least \$28.25 in adjusted earnings per common share ("Adjusted EPS"), in each case for the year ending December 31, 2023 ("FY 2023"). This guidance is consistent with the guidance issued in Humana's press release dated April 26, 2023. The date and time of presentations to investors are available via the Investor Relations calendar of events on the Company's website at www.humana.com.

The Company has included Adjusted EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accounting Principles ("GAAP"). Management believes that this measure, when presented in conjunction with the comparable measure of GAAP EPS, is useful to both management and its investors in analyzing the Company's ongoing business and operating performance. Consequently, management uses Adjusted EPS as an indicator of the Company's business performance, as well as for operational planning and decision making purposes. Adjusted EPS should be considered in addition to, but not as a substitute for, or superior to, GAAP EPS. A reconciliation of GAAP EPS to Adjusted EPS follows:

Diluted earnings per common share	FY 2023 Guidance
GAAP	at least \$27.88
Amortization of identifiable intangibles	0.50
Put/call valuation adjustments associated with Company's non-	
consolidating minority interest investments	0.42
Transaction and integration costs	(0.41)
Change in fair market value of publicly-traded equity securities	(0.01)
Impact of exit of employer group commercial medical products business	0.13
Tax impact of non-GAAP adjustments	(0.26)
Adjusted (non-GAAP) – FY 2023 projected	at least \$28.25

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

HUMANA INC.

BY: /s/ John-Paul W. Felter

John-Paul W. Felter

Senior Vice President, Chief Accounting Officer & Controller

(Principal Accounting Officer)

Dated: June 1, 2023